Skip to main content
. Author manuscript; available in PMC: 2021 Jun 9.
Published in final edited form as: J Hepatol. 2020 Dec 17;74(6):1416–1428. doi: 10.1016/j.jhep.2020.12.010

Fig. 5. Prevention of HSC activation and myofibroblast expansion, normalisation of ‘reactive ducts’ phenotype in livers of BALB/c.Abcb4−/− mice with hABCB4v6 mRNA treatment.

Fig. 5.

(A) Representative images of immunostaining for HSC/myofibroblast activation marker α-SMA (upper row, ×50, scale bar 200 μm), ductular reaction markers αKβ9 (middle row, ×200, scale bar 50 μm) and integrin avb6 (lower row, ×200, scale bar 50 μm) with morphometric quantification (B–D). Data are mean ± SEM (n = 4/7/7 individual animals per bar, average of 10 random HPF analysed per animal). The p value indicated as compared with eGFP group (ANOVA). hABCB4, human ATP-binding cassette 4; HPF, high-power field; HSC, hepatic stellate cell; WT, wild-type.